A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2014
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 14 Oct 2013 Status changed from active, no longer recruiting to completed, as reported in a Hanmi Pharmaceutical media release.
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.